Last reviewed · How we verify
A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating patients with metastatic or recurrent adenocarcinoma.
Details
| Lead sponsor | MacroGenics |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 53 |
| Start date | 2004-12 |
| Completion | 2008-05 |
Conditions
- Cancer
Interventions
- monoclonal antibody RAV12
Primary outcomes
- Toxicity by CTCAE — Days 1-50
Countries
United States